SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Hagiwara Akifumi)
 

Sökning: WFRF:(Hagiwara Akifumi) > Incidence, molecula...

Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation

Hagiwara, Akifumi (författare)
UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Deptartment of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan
Schlossman, Jacob (författare)
UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States
Shabani, Soroush (författare)
UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States
visa fler...
Raymond, Catalina (författare)
UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Deptartment of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States
Tatekawa, Hiroyuki (författare)
UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Deptartment of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Department of Diagnostic and Interventional Radiology, Osaka City University Graduate School of Medicine, Osaka, Japan
Abrey, Lauren E. (författare)
F. Hoffman-La Roche, Ltd., Basel, Switzerland
Garcia, Josep (författare)
F. Hoffman-La Roche, Ltd., Basel, Switzerland
Chinot, Olivier (författare)
Aix-Marseille University, AP-HM, Service de Neuro-Oncologie, CHU Timone, Marseille, France
Saran, Frank (författare)
The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Nishikawa, Ryo (författare)
Saitama Medical University, Saitama, Japan
Henriksson, Roger (författare)
Umeå universitet,Onkologi,Regional Cancer Center Stockholm, Stockholm, Sweden
Mason, Warren P. (författare)
Princess Margaret Hospital, Toronto, Canada
Wick, Wolfgang (författare)
Clinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
Cloughesy, Timothy F. (författare)
UCLA Brain Research Institute (BRI), David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States
Ellingson, Benjamin M. (författare)
UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Deptartment of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; UCLA Brain Research Institute (BRI), David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; UCLA Neuro-Oncology Program, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Department of Physics and Biology in Medicine, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, CA, Los Angeles, United States; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, CA, Los Angeles, United States
visa färre...
 (creator_code:org_t)
2022-07-17
2022
Engelska.
Ingår i: Journal of Neuro-Oncology. - : Springer. - 0167-594X .- 1573-7373. ; 159, s. 509-518
Relaterad länk:
https://urn.kb.se/re...
visa fler...
https://doi.org/10.1...
visa färre...
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Purpose: Pseudoprogression (PsP) remains an elusive and clinically important, yet ill-defined, phenomena that, generally, involves a period of early radiographic progression (enhancement) followed by a period of radiographic stability or regression. In the current study, we utilized data from the control arm of a phase III clinical trial in newly-diagnosed glioblastoma to explore imaging characteristics of “clinically-defined PsP”, or early radiographic progression (PFS < 6 months from chemoradiation) followed by a long post-progression residual overall survival (ROS > 12 months).Methods: One hundred sixty-nine patients with newly-diagnosed GBM from the control arm of the AVAglio trial (NCT00943826) who presented with early radiographic progressive disease (PD) (< 6 months) were included. Clinical characteristics, topographical patterns, and radiomic features were compared between newly-diagnosed GBM exhibiting early PD and early death (< 12-month ROS, “true PD”) with those exhibiting early PD and a long residual survival (> 12-month ROS, “clinically-defined PsP”).Results: “Clinically-defined PsP” occurred to 38.5% of patients with early PD, and was more associated with MGMT methylation (P = 0.02), younger age (P = 0.003), better neurological performance (P = 0.01), and lower contrast-enhancing tumor volume (P = 0.002) at baseline. GBM showing “true PD” occurred more frequently in the right internal capsule, thalamus, lentiform nucleus, and temporal lobe than those with “clinical PsP”. Radiomic analysis predicted “clinical PsP” with > 70% accuracy on the validation dataset.Conclusion: Patients with early PD that eventually exhibit “clinically-defined PsP” have distinct clinical, molecular, and MRI characteristics. This information may be useful for treating clinicians to better understand the potential risks and outcome in patients exhibiting early radiographic changes following chemoradiation.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Chemoradiation
Clinical trial
Newly diagnosed glioblastoma
Pseudoprogression
Radiomics

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy